relapsing remitting multiple sclerosis

August 11, 2016August 11, 2016

Improving Confidence of RRMS Patients May Enhance Quality of Life, Decrease Depression, Study Finds

News

Increasing a person’s confidence that they can complete tasks and reach goals in specific situations may benefit patients with relapsing-remitting multiple sclerosis (RRMS). In a new ... Read more

August 5, 2016August 5, 2016

Gut Microbiota Is Growing Focus of Multiple Sclerosis Research, Though Treatments Are Few

Multiple Sclerosis News

Gut microbiota (the ecological community of microorganisms that live in the gut) may be an important environmental risk factor for multiple sclerosis (MS). This suggests that ... Read more

April 8, 2016

4 Types of Multiple Sclerosis

The clinical manifestation of symptoms (CMS) that lead to multiple sclerosis starts with the first symptomatic ‘attack’ indicative of the first signs of neurological damage (demyelination), ... Read more

December 7, 2015

Last Week’s Top-3 Most Read Posts On Multiple Sclerosis

Read the Articles Here: EMD Serono Announces Publication of PRISMS-15 Years Follow-up Study Results on Rebif for Relapsing–Remitting Multiple Sclerosis New Study Unravels How Myelin is ... Read more

October 19, 2015October 19, 2015

Teva Pharmaceutical Industries’ COPAXONE 40 mg/mL Three-times-a-week Approved in Russia for Relapsing-Remitting Multiple Sclerosis

News

Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions to millions of patients every day, recently announced the approval of ... Read more

October 16, 2015October 16, 2015

GATE Trial Supports Generic Glatiramer Acetate as an Alternative Therapy for Relapsing-Remitting Multiple Sclerosis

News

The Glatiramer Acetate Clinical Trial to Assess Equivalence With Copaxone  (GATE) seems to be the first phase 3 clinical trial to test a generic disease-modifying medication ... Read more

October 14, 2015October 14, 2015

Study Reports No Influence of Vitamin D Supplementation on Inflammation in Relapsing-Remitting Multiple Sclerosis

News

A recent study of people with relapsing remitting multiple sclerosis (RRMS) found that high-dose oral vitamin D3 supplementation did not influence markers of inflammation. Inflammation is a reaction to ... Read more

October 12, 2015October 12, 2015

Updates On Relapsing-Remitting Multiple Sclerosis

Genzyme, a Sanofi company, recently announced novel positive 5-year experimental data from the extension study of Lemtrada® (alemtuzumab) in individuals with relapsing-remitting multiple sclerosis (RRMS). Read the findings here: http://bit.ly/1LEWNQV ... Read more

October 8, 2015October 8, 2015

Biogen to Present Update on TECFIDERA (Dimethyl Fumarate) for Early Stage Relapsing-Remitting Multiple Sclerosis at ECTRIMS 2015

News

Biogen Idec is scheduled to present the latest efficacy and safety profile updates on TECFIDERA (dimethyl fumarate), its lead treatment for relapsing-remitting multiple sclerosis (RRMS), during the 31st Congress ... Read more

October 7, 2015October 7, 2015

Genzyme to Present vs.MS Global Survey Data on Relapsing Multiple Sclerosis Challenges at ECTRIMS

News

Genzyme recently announced a novel worldwide initiative called vs.MS, whose goal is to increase awareness of the psychical and emotional toll of relapsing multiple sclerosis (RMS) ... Read more

September 30, 2015September 30, 2015

Teva’s COPAXONE Approved in Japan for the Prevention of Relapse Remitting Multiple Sclerosis

News

Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions, recently announced that the Japanese Ministry of Health, Labour and Welfare ... Read more

September 22, 2015September 22, 2015

Clinical Benefit of Relapsing-Remitting Multiple Sclerosis Therapies Highlighted in Review

Multiple Sclerosis News, News

A review study recently published in the journal Cochrane Database of Systematic Review (CDSR) focused on the clinical benefit of different therapies available for relapsing-remitting multiple sclerosis ... Read more

August 24, 2015August 24, 2015

Novartis Acquires Remaining Rights to Ofatumumab by GSK for Multiple Sclerosis and Other Autoimmune Diseases

Multiple Sclerosis News, News

Pharmaceutical giant Novartis recently announced it has signed an agreement with GlaxoSmithKline for exclusive rights to GSK’s investigational CD20-specific monoclonal antibody, Ofatumumab, indicated for relapsing remitting multiple sclerosis ... Read more

August 10, 2015August 20, 2015

Benefits of Exercise For Kids With MS Touted in New Study

Multiple Sclerosis News, News

A recent research study focused on whether regular exercise can benefit children with multiple sclerosis (MS). The article appeared in the August 12, 2015, online issue ... Read more

August 6, 2015August 10, 2015

Could Salt Intake be an MS Risk Factor?

Multiple Sclerosis News, News

Most people know that eating too much salt is bad for your health, but a new study suggests that it could also increase the risk for ... Read more

July 22, 2015July 23, 2015

New Study Evaluates The Role of MRI in Monitoring MS Progression

News

Multiple sclerosis (MS) is a devastating, progressive disease of the nervous system. It is caused by loss of myelin, a fatty substance that wraps around nerve cells ... Read more

June 29, 2015June 29, 2015

Novartis’ Gilenya Found to Have Long-Term Positive Effects on Patients with Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis News, News

A new study recently published in the Journal of Neurology, Neurosurgery and Psychiatry revealed that long-term fingolimod therapy (marketed as Gilenya by Novartis) can maintain a ... Read more

May 11, 2015May 11, 2015

Problem Drinking in MS Associated with Anxiety and Family History

Multiple Sclerosis News, News

Multiple sclerosis (MS) presents many life-altering challenges, but most patients naturally focus most often on the physical challenges associated with the condition: problems with movement, sensation and vision ... Read more

May 7, 2015May 7, 2015

Myelin Repair Foundation and NIH to Study Guanabenz for MS

Multiple Sclerosis News, News

The Myelin Repair Foundation (MRF) and National Institutes of Health (NIH) will initiate a clinical trial of guanabenz in people with multiple sclerosis (MS). Guanabenz is FDA-approved for high ... Read more

April 27, 2015April 27, 2015

FDA Accepts Bayer’s BETACONNECT License Application for Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis News, News

Bayer HealthCare recently announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental Biologics License Application (sBLA) for BETACONNECT for the treatment ... Read more

April 23, 2015April 23, 2015

Phase III Study of Experimental MS Therapy Meets Primary Endpoint, Results to be Presented at ANN Meeting

Multiple Sclerosis News, News

MedDay, a French biotechnology company that studies treatments for nervous system disorders, including multiple sclerosis, announced that MD1003, a highly-concentrated biotin, is effective for treatment of progressive ... Read more

April 22, 2015April 22, 2015

Biogen To Present Data On The Effectiveness of TECFIDERA In Newly-Diagnosed MS Patients During The ANN Annual Meeting

Multiple Sclerosis News, News

Biogen has recently announced novel results to support the effectiveness of TECFIDERA (dimethyl fumarate) in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results revealed that TECFIDERA significantly reduced ... Read more

April 22, 2015April 22, 2015

Two Already-Approved Medications Could Treat MS

Multiple Sclerosis News, News

Two already available medications could be used to treat multiple sclerosis (MS). In a new study titled, “Drug Based Modulation of Endogenous Stem Cells,” published in the journal Nature on ... Read more

April 17, 2015April 17, 2015

First Generic Version of Copaxone Approved by FDA to Treat Multiple Sclerosis

Multiple Sclerosis News, News

The U.S. Food and Drug Administration (FDA) has announced the approval of the first generic version of Copaxone (glatiramer acetate injection) for the treatment of relapsing forms of multiple ... Read more

April 16, 2015April 18, 2015

Co-existing MS and FM Influences Pain Threshold, According to New Study

Multiple Sclerosis News, News

People with multiple sclerosis (MS) commonly experience a low pain threshold and sensitivity to heat and cold. If a person has multiple sclerosis along with fibromyalgia ... Read more

April 13, 2015October 20, 2015

Biogen to Focus on RRMS Disease Management, Treatment at Upcoming Conference

Multiple Sclerosis News, News

Biogen plans to present new clinical data at the 67th American Academy of Neurology (AAN) Annual Meeting in Washington D.C., April 18 – 25, 2015, including numerous ... Read more

February 16, 2015October 6, 2015

Stem Cells Used to Treat Secondary Progressive Patients in Clinical Trial

Multiple Sclerosis News, News

What may work better than existing drugs to treat severe multiple sclerosis? Stem cells. A phase 2 clinical study from an international group of research centers ... Read more

January 30, 2015July 19, 2016

MS Inspiration Offers Sports Tickets on Campaign with Tyler Campbell and Chris Wright

Multiple Sclerosis News, News

Tyler Campbell, the son of the NFL Hall of Famer Earl Campbell, and professional basketball player Chris Wright are not only well-known sports figures, but also ... Read more

December 19, 2014December 19, 2014

Mapi Pharma Treats First RRMS Patient with Once-A-Month GA Depot

Multiple Sclerosis News, News

Mapi Pharma Ltd., a development stage pharmaceutical company specializing in the development of high-barrier to entry and high-added value generic drugs, announced it has treated the first patient ... Read more

December 2, 2014December 2, 2014

Aubagio for Relapsing-Remitting MS Now Funded in Alberta

News

Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for rare and orphan diseases, has just announced the Alberta ... Read more

November 24, 2014November 24, 2014

Experimental Drug for RRMS, SPMS Enters Phase 2 Trial

Multiple Sclerosis News, News

Lexington, MA-based biopharmaceutical company Xenetic Biosciences, Inc. has just announced its new license partner Pharmsynthez has completed dosing in its ongoing Phase 2 clinical trial with pipeline product MyeloXen™ ... Read more

November 17, 2014July 19, 2016

Teva Pursues Regulatory Approval in Japan for MS Drug Copaxone

News

Teva Pharmaceutical Industries Ltd., the company that developed the injectable multiple sclerosis treatment Copaxone (Glatiramer acetate),  has announced their pursuit of regulatory approval in Japan. This ... Read more

November 5, 2014November 5, 2014

Genzyme Clinical Trial for Relapsing-Remitting MS Enrolls 1st Patient

Multiple Sclerosis News, News

Sanofi subsidiary and rare disease treatment specialist Genzyme has just announced the successful enrollment of the first participant in their multicenter Phase II clinical trial for the company’s ... Read more

October 21, 2014June 30, 2015

David Osmond Sings for Novartis MS Awareness Campaign

News

A member of the musical Osmond family, David Osmond, recently released a music video for his inspirational song “I Can Do This.” He has dedicated it ... Read more

October 9, 2014October 9, 2014

New Long-lasting Multiple Sclerosis Drug Will Come At a Steep Price

Multiple Sclerosis News, News

Now more than ever, groundbreaking, new therapies for chronic diseases and infections come with high price tags. Earlier in the year, Gilead Sciences’ drug Sovaldi for Hepatitis ... Read more

September 24, 2014September 24, 2014

Multiple Sclerosis Summit in Quebec to Feature “Deepelling” As Encouragement for Active MS Lifestyles

News

International conferences on multiple sclerosis (MS) typically gather the most accomplished experts and leading biotech companies under one roof to exchange discoveries and celebrate new hope ... Read more

September 15, 2014November 14, 2016

Teva, Active Biotech Present Positive Findings for RRMS Experimental Therapy Laquinimod

Multiple Sclerosis News, News

During the 30th Congress of the European Committee for Research and Treatment in Multiple Sclerosis (ECTRIMS) last week in Boston, Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), together ... Read more

September 11, 2014July 19, 2016

Receptos to Present Data on RMS Treatment Trial at MSBoston 2014

Multiple Sclerosis News, News

Biopharmaceutical company Receptos, Inc. announced that they will review data from the phase 2 portion of the RADIANCE trial, the company’s phase 2 / 3 study testing RPC1063 in ... Read more

September 8, 2014June 30, 2015

Novartis to Present New Gilenya Data at ACTRIMS-ECTRIMS Meeting

Multiple Sclerosis News, News

Those attending this week’s ACTRIMS-ECTRIMS convention set to take place on the 10th of September until the 13th in Boston, can expect Swiss pharmaceutical company Novartis to present promising findings on ... Read more

September 4, 2014September 4, 2014

Walking Speed in MS Patients May Indicate Worsening of Disease

Multiple Sclerosis News, News

A dynamic research team composed of doctors and scientists recently completed and published a study that sought to gain a better understanding of walking impairment, as ... Read more